Transcode Therapeutics Stock Market Value
| RNAZ Stock | USD 0.38 0.04 11.56% |
| Symbol | Transcode |
Transcode Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Transcode Therapeutics. If investors know Transcode will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Transcode Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 168.84 | Return On Assets (2.08) | Return On Equity (10.49) |
The market value of Transcode Therapeutics is measured differently than its book value, which is the value of Transcode that is recorded on the company's balance sheet. Investors also form their own opinion of Transcode Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Transcode Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Transcode Therapeutics' market value can be influenced by many factors that don't directly affect Transcode Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Transcode Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Transcode Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Transcode Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Transcode Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Transcode Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Transcode Therapeutics.
| 12/02/2022 |
| 11/21/2024 |
If you would invest 0.00 in Transcode Therapeutics on December 2, 2022 and sell it all today you would earn a total of 0.00 from holding Transcode Therapeutics or generate 0.0% return on investment in Transcode Therapeutics over 720 days. Transcode Therapeutics is related to or competes with Xenetic Biosciences, Reviva Pharmaceuticals, Eyenovia, Cognition Therapeutics, Kodiak Sciences, Immix Biopharma, and Cns Pharmaceuticals. TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and... More
Transcode Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Transcode Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Transcode Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 7.66 | |||
| Information Ratio | 0.0671 | |||
| Maximum Drawdown | 68.8 | |||
| Value At Risk | (11.43) | |||
| Potential Upside | 22.0 |
Transcode Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Transcode Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Transcode Therapeutics' standard deviation. In reality, there are many statistical measures that can use Transcode Therapeutics historical prices to predict the future Transcode Therapeutics' volatility.| Risk Adjusted Performance | 0.066 | |||
| Jensen Alpha | 1.05 | |||
| Total Risk Alpha | (0.46) | |||
| Sortino Ratio | 0.1037 | |||
| Treynor Ratio | (0.44) |
Transcode Therapeutics Backtested Returns
Transcode Therapeutics is dangerous given 3 months investment horizon. Transcode Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.0955, which indicates the firm had a 0.0955% return per unit of risk over the last 3 months. We were able to analyze twenty-nine different technical indicators, which can help you to evaluate if expected returns of 1.15% are justified by taking the suggested risk. Use Transcode Therapeutics Semi Deviation of 6.52, coefficient of variation of 1329.82, and Risk Adjusted Performance of 0.066 to evaluate company specific risk that cannot be diversified away. Transcode Therapeutics holds a performance score of 7 on a scale of zero to a hundred. The entity has a beta of -1.99, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Transcode Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Transcode Therapeutics is expected to outperform it. Use Transcode Therapeutics total risk alpha and the relationship between the downside variance and relative strength index , to analyze future returns on Transcode Therapeutics.
Auto-correlation | 0.53 |
Modest predictability
Transcode Therapeutics has modest predictability. Overlapping area represents the amount of predictability between Transcode Therapeutics time series from 2nd of December 2022 to 27th of November 2023 and 27th of November 2023 to 21st of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Transcode Therapeutics price movement. The serial correlation of 0.53 indicates that about 53.0% of current Transcode Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.53 | |
| Spearman Rank Test | 0.61 | |
| Residual Average | 0.0 | |
| Price Variance | 5.36 |
Transcode Therapeutics lagged returns against current returns
Autocorrelation, which is Transcode Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Transcode Therapeutics' stock expected returns. We can calculate the autocorrelation of Transcode Therapeutics returns to help us make a trade decision. For example, suppose you find that Transcode Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Transcode Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Transcode Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Transcode Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Transcode Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Transcode Therapeutics Lagged Returns
When evaluating Transcode Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Transcode Therapeutics stock have on its future price. Transcode Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Transcode Therapeutics autocorrelation shows the relationship between Transcode Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Transcode Therapeutics.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Transcode Stock Analysis
When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.